peptides for longevity
longevity is where peptide marketing runs furthest ahead of the data. claims ranked by evidence quality.
two compounds on this page have narrow-indication approvals (tesamorelin for hiv lipodystrophy, ss-31 as elamipretide accelerated-approved september 2025 for barth syndrome). one is a single-lab russian icon (epithalon, khavinson lab st. petersburg). one is a 2015 discovery that opened a new class of mitochondrial-derived peptides (mots-c, pinchas cohen and changhan lee at usc). one is not a peptide at all (nad+, a dinucleotide cofactor).
mitochondria, immune, and metabolic aging.
compounds with regulatory milestones, mechanistic specificity, or clinical-trial data on aging-adjacent biology.
- tesamorelin (tier S) — ghrh analog, fda-approved nov 2010 as egrifta for hiv-associated lipodystrophy.
- ss-31 (tier A) — mitochondria-targeted tetrapeptide (elamipretide), hazel szeto lab cornell, developed by stealth biotherapeutics.
- mots-c (tier B) — mitochondrial-derived peptide, lee group at usc, 2015. encoded inside the mitochondrial 12s rrna gene.
- humanin (tier C) — the first mitochondrial-derived peptide (hashimoto 2001), encoded inside the mt-rnr2 gene. cytoprotective biology in cells and rodents.
- thymosin alpha-1 (tier C) — 28-amino-acid immune peptide. approved as zadaxin in 35+ countries for chronic hepatitis b and as adjunct in sepsis.
where the story outruns replication.
compounds with high name recognition in longevity discussion and thinner independent evidence than the marketing suggests.
- nad+ (tier D) — not a peptide. dinucleotide cofactor central to mitochondrial energy and repair pathways.
- epithalon (tier C) — khavinson-program tetrapeptide (ala-glu-asp-gly), st. petersburg institute of bioregulation and gerontology.
- pinealon (tier C) — khavinson tripeptide (glu-asp-arg) with neuroprotection claims.
- glutathione (tier D) — endogenous redox tripeptide (gamma-glu-cys-gly) tied to oxidative-stress biology.
- 5-amino-1mq (tier D) — not a peptide. small-molecule nnmt inhibitor, neelakantan et al sci reports 2018.
specific-question reference.
which longevity peptide has the strongest regulatory milestone?
ss-31 (elamipretide), FDA accelerated approval september 2025 for Barth syndrome, a rare cardiolipin-deficiency cardiomyopathy. tesamorelin has older FDA approval (november 2010) for HIV-associated visceral lipodystrophy. both are narrow indications. neither is an approval for healthy-adult anti-aging dosing.
which compound is most interesting mechanistically?
mots-c, identified by lee and cohen at usc in 2015. the first member of a class of peptides encoded inside the mitochondrial genome itself (the 12s rrna open reading frame), signaling on amp-kinase and metabolic flexibility. the human clinical record is still early.
why is epithalon not ranked higher?
the longevity claim depends on khavinson-lab literature with minimal independent western replication. iconic does not mean settled. the single-lab pattern is the weakness.
what is the safest way to read longevity claims?
as evidence tiers. approved narrow indication, controlled human trial, preclinical biology, mechanistic hypothesis, and marketing narrative are different categories that should not be averaged.
what the safety literature reports.
what safety gap matters most in longevity peptides?
duration. short-term and preclinical signals do not characterize chronic healthy-adult exposure. longevity dosing protocols imply years of use against trial data measured in weeks or months.
why is nad+ included if it is not a peptide?
longevity search traffic surfaces it, and excluding it leaves readers without a comparison. it is a dinucleotide cofactor, not a peptide. the iv-clinic outcome claim is not supported by controlled human data, and the page tiers it accordingly rather than pretending it fits the class.
what claim is intentionally avoided?
that any compound extends human lifespan. this page reports mechanisms, trial record, and regulatory status. it does not make lifespan promises.
related comparisons
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.